InnoCare Pharma Ltd. (9969) Gets a Buy from UBS
I'm PortAI, I can summarize articles.
UBS analyst Chen Chen maintains a Buy rating on InnoCare Pharma Ltd., setting a price target of HK$23.60. Chen, who covers the Healthcare sector, has a 50.3% average return and a 68.18% success rate on recommended stocks. The analyst consensus suggests a Strong Buy rating for InnoCare Pharma Ltd. with an average price target of HK$21.80.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments